65 completed, 48 recruiting, 32 unknown, 21 terminated. 106 Phase 2, 42 Phase 1, 22 Not applicable, 19 Phase 3, 5 Early Phase 1.
Follow this condition Literature Review of Colorectal Cancer Metastatic trials Research Report on Colorectal Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Efficacy and Safety of Ultrasound-Guided Microwave Ablation for Hepatic Metastatic Nodules Ultrasound-Guided Microwave Ablation - Liver Metastases, Hepatic Metastases | Not applicable | Not yet recruiting | Assiut University | 30 | 2026-11-01 | 2026-10-13 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab - Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 270 | 2026-07-30 | 2026-07-27 |
| SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study SHR-A1904 - Colorectal Cancer Metastatic | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 17 | 2026-07-28 | 2026-07-14 |
| A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer HDM2017, Fruquintinib - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 120 | 2026-07-15 | 2026-06-02 |
| BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases Balstilimab (BAL), Botensilimab (BOT), agenT-797 - Colorectal Cancer Metastatic | Phase 2 | Recruiting | Darren Sigal, MD | 17 | 2026-06-10 | 2026-08-10 |
| China Metastatic Liver Cancer Clinical Registry Cohort Database Standard of Care for Metastatic Liver Cancer - Liver Metastases, Metastases to Liver | Recruiting | Anhui Provincial Hospital | 2000 | 2026-06-01 | 2026-05-22 | |
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC) Modified early post-operative intraperitoneal chemotherapy (mEPIC) - Peritoneal Carcinomatosis, Appendiceal Neoplasms | Phase 2 | Recruiting | Ciusss de L'Est de l'Île de Montréal | 25 | 2026-05-01 | 2026-05-14 |
| Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer yFMT - Colorectal Cancer Metastatic, Fecal Microbiota Transplantation | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 10 | 2026-03-31 | 2026-03-20 |
| A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma - Triple Negative Breast Cancer Metastatic, Melanoma Metastatic | Phase 2 | Recruiting | Fudan University | 95 | 2026-03-30 | 2026-07-13 |
| A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer BioTTT001 hepatic artery infusion, toripalimab, regorafenib - Colorectal Cancer Metastatic | Phase 1 | Not yet recruiting | China Medical University, China | 60 | 2026-03-01 | 2026-01-07 |
| Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer maintenance therapy plus lubiprostone, maintenance therapy - Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 124 | 2026-02-24 | 2026-02-12 |
| COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab - Colorectal Cancer Metastatic, Colorectal Cancer Stage III | Early Phase 1 | Recruiting | Biogenea Pharmaceuticals Ltd. | 12 | 2026-02-02 | 2026-01-09 |
| Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer EB-DUO-CAR-NK-CEA/GCC (IV) - Colorectal Cancer Metastatic, Adenocarcinoma of Colon | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 48 | 2026-02-01 | 2026-03-10 |
| Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy Hepatic Artery Infusion Pump (HAIP), Standard Treatment, Community Treatment - Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Michael J Cavnar, MD | 80 | 2026-01-23 | 2026-02-04 |
| Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373 - Colorectal Cancer Metastatic | Early Phase 1 | Recruiting | Northwell Health | 10 | 2025-12-10 | 2026-06-24 |
| INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases Nelitolimod - Colorectal Cancer Metastatic | Early Phase 1 | Recruiting | Northwell Health | 10 | 2025-11-17 | 2026-03-19 |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC ABT-301, Tislelizumab, Bevacizumab (Avastin) - Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Anbogen Therapeutics, Inc. | 66 | 2025-11-01 | 2025-11-24 |
| STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer standard second line treatment, at discretion of the investigator, Regorafenib (BAY73-4506) - Colorectal Cancer Metastatic | Phase 2 | Recruiting | National Cancer Institute, Naples | 60 | 2025-10-16 | 2026-10-13 |
| Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection Liver Transplant Surgery, Colorectal Cancer Metastatic | Recruiting | Northwestern University | 80 | 2025-08-27 | 2026-07-10 |
Showing 20 of 212. Sign in to see all of them.
Colorectal Neoplasms (77) · Neoplasm Metastasis (15) · Neoplasms (11) · Colonic Neoplasms (9) · Liver Neoplasms (5) · Peritoneal Neoplasms (5) · Carcinoma, Hepatocellular (4) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Appendiceal Neoplasms (3) · Pancreatic Neoplasms (3) · Rectal Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma (2) · Carcinoma, Renal Cell (2)
Neoplasms by Site (96) · Neoplasms (94) · Digestive System Diseases (91) · Digestive System Neoplasms (91) · Gastrointestinal Diseases (86) · Gastrointestinal Neoplasms (85) · Intestinal Diseases (84) · Intestinal Neoplasms (84) · Colonic Diseases (82) · Rectal Diseases (79) · Pathologic Processes (20) · Pathological Conditions, Signs and Symptoms (20) · Neoplastic Processes (16) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (10)
Bevacizumab (30) · Cetuximab (21) · Capecitabine (20) · Irinotecan (20) · Fluorouracil (19) · Leucovorin (18) · Oxaliplatin (16) · regorafenib (12) · Panitumumab (9) · Nivolumab (8) · aflibercept (8) · Folfox protocol (7) · Drug Therapy (5) · sintilimab (5) · trifluridine tipiracil drug combination (5)
Sun Yat-sen University (13) · Fudan University (8) · Sanofi (6) · Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · GERCOR - Multidisciplinary Oncology Cooperative Group (3) · Grupo Espanol Multidisciplinario del Cancer Digestivo (3) · Gruppo Oncologico del Nord-Ovest (3) · National Cancer Institute, Naples (3) · The Netherlands Cancer Institute (3) · Amsterdam UMC, location VUmc (2) · Assiut University (2) · China Medical University, China (2) · Federation Francophone de Cancerologie Digestive (2) · Harbin Medical University (2)
China (50) · United States (44) · France (23) · Italy (18) · Spain (17) · Germany (15) · United Kingdom (11) · Canada (10) · Netherlands (9) · Belgium (7) · Israel (6) · South Korea (6) · Norway (5) · Australia (4) · Denmark (4)
A Bardelli, Prof (2) · A Cervantes, Prof (2) · Bernard Nordlinger, Pr. (2) · Funan Liu, MD (2) · J Tabernero, Prof (2) · Jean Lachaine, PhD (2) · R Bernards, Prof (2) · R Salazar, MD, PhD (2) · Ruihua Xu, M.D (2) · S Siena, Prof (2) · S Tejpar, Prof (2) · Zhenning Wang, MD (2) · Agnieszka Michael (1)
PMID 14551293, PMID 14993230, PMID 15175435, PMID 15269313, PMID 16814439, PMID 17141360, PMID 17289377, PMID 18049451, PMID 18537129, PMID 18781585, PMID 19339720, PMID 19571295, PMID 19782876, PMID 20145956, PMID 20702138, PMID 20711635, PMID 21246515, PMID 21295962, PMID 21744871, PMID 21861888, PMID 22289566, PMID 22446022, PMID 22988651, PMID 23053552, PMID 23129580, PMID 23493136, PMID 23631493, PMID 24377653, PMID 24718886, PMID 24981364, PMID 25088940, PMID 25115304, PMID 25154721, PMID 25280404, PMID 25293556, PMID 25500543, PMID 25862517, PMID 26141683, PMID 26541606, PMID 26903575, PMID 27986363, PMID 28351831, PMID 28592624, PMID 28781171, PMID 28911067, PMID 29097493, PMID 29273089, PMID 29942666, PMID 30117334, PMID 30131226
2017 (5), 2016 (2), 2018 (2), 2009 (1), 2014 (1), 2023 (1), 2025 (1), P30CA014089 (1), P30CA138292 (1), P50CA062924 (1)